Affinage

FBXL2

F-box/LRR-repeat protein 2 · UniProt Q9UKC9

Length
423 aa
Mass
47.1 kDa
Annotated
2026-04-28
39 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FBXL2 is the substrate-recognition subunit of an SCF-type E3 ubiquitin ligase that targets a remarkably broad set of substrates for proteasomal degradation, functioning as a central regulator of calcium signaling, cell cycle progression, receptor tyrosine kinase turnover, and inflammatory responses. Uniquely among F-box proteins, FBXL2 requires geranylgeranylation of its C-terminal CAAX motif for membrane localization and substrate engagement, and it recognizes substrates predominantly through calmodulin-binding motifs rather than canonical phosphodegrons — with calmodulin competing directly for substrate access (PMID:15893726, PMID:22020328, PMID:21343341). Key substrates include IP3R3 (controlling ER-to-mitochondria Ca²⁺ transfer and apoptosis), cyclin D2/D3 and Aurora B (enforcing cell cycle arrest), p85β (modulating PI3K signaling), EGFR and HER2 (regulating receptor tyrosine kinase abundance), NLRP3/pro-IL-1β and TRAF2/6 (suppressing inflammation), and transcription factors FoxM1, T-bet, and E47 (PMID:28614300, PMID:22323446, PMID:23928698, PMID:23604317, PMID:34635651, PMID:41612000, PMID:37004285, PMID:26790640). FBXL2 itself is negatively regulated by FBXO3-mediated ubiquitination, by O-GlcNAcylation-induced degradation, and by TNF-α–JNK–SP1 transcriptional repression, establishing multiple feedback tiers that tune its activity (PMID:26674878, PMID:31679690, PMID:32205409).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2005 High

    The discovery that FBXL2 is geranylgeranylated at its CAAX motif and that this lipid modification is required for its membrane association and protein–protein interaction established a unique biochemical feature distinguishing FBXL2 from other F-box proteins.

    Evidence Metabolic [³H]mevalonate labeling, Co-IP with HCV NS5A, dominant-negative and siRNA rescue in cell culture

    PMID:15893726

    Open questions at the time
    • Whether geranylgeranylation is constitutive or regulated was not addressed
    • The endogenous cellular substrates were not identified in this study
  2. 2011 High

    Identification of cyclin D3, cyclin D2, and CCTα as FBXL2 substrates revealed that FBXL2 recognizes calmodulin-binding motifs rather than classical phosphodegrons, and that calmodulin directly competes with FBXL2 for substrate binding — establishing a novel substrate-recognition paradigm for SCF ligases.

    Evidence Polyubiquitination assays, calmodulin competition mapping, siRNA/overexpression, cell cycle analysis, xenograft and murine infection models

    PMID:21343341 PMID:22020328 PMID:22024926 PMID:22323446

    Open questions at the time
    • Structural basis of the calmodulin-binding motif recognition by FBXL2 leucine-rich repeats remains unresolved
    • Whether all FBXL2 substrates require calmodulin-competitive recognition was not tested
  3. 2012 High

    Demonstration that FBXL2 ubiquitinates APP and reduces Aβ secretion extended the substrate repertoire beyond cell cycle regulators to neurodegeneration-relevant proteins, showing FBXL2 can control membrane protein endocytosis and lipid raft localization.

    Evidence Co-IP, ubiquitination assay, APP localization studies, transgenic mouse model

    PMID:22399757

    Open questions at the time
    • The degron within APP recognized by FBXL2 was not mapped
    • Physiological relevance in human Alzheimer's disease tissue not established
  4. 2013 High

    Discovery that FBXL2 targets free p85β (not p85-p110 heterodimers) for degradation in a CAAX- and phosphorylation-dependent manner, and that it ubiquitinates Aurora B at specific lysines, demonstrated how FBXL2 integrates signal-dependent substrate selection with cell cycle and PI3K pathway control.

    Evidence MS-based F-box interactome, reciprocal Co-IP, lysine mutagenesis (Aurora B K102/103/207R), phosphosite mutagenesis (p85β Y655), xenograft model

    PMID:23604317 PMID:23928698

    Open questions at the time
    • Whether phosphorylation-gated recognition of p85β represents an exception to the calmodulin-motif paradigm is unclear
    • No structural model of FBXL2-substrate complexes exists
  5. 2015 Medium

    The finding that FBXO3 ubiquitinates and degrades FBXL2 — and that pharmacological FBXO3 inhibition (BC-1215) stabilizes FBXL2 and restores substrate degradation — established the FBXO3–FBXL2 axis as a druggable regulatory tier controlling FBXL2 activity, initially demonstrated for TRAF2 and RIM1α in neuropathic pain.

    Evidence siRNA, intrathecal BC-1215, Co-IP, electrophysiology, behavioral allodynia testing in spinal nerve ligation models

    PMID:26674878 PMID:27629721

    Open questions at the time
    • The ubiquitination sites on FBXL2 targeted by FBXO3 are not mapped
    • Whether FBXO3 regulation of FBXL2 is tissue-specific was not examined
  6. 2017 High

    Identification of IP3R3 as an FBXL2 substrate that controls ER-to-mitochondria Ca²⁺ flux and apoptosis sensitivity — with PTEN competing with FBXL2 for IP3R3 binding — placed FBXL2 at the intersection of tumor suppression, calcium homeostasis, and cell death signaling.

    Evidence Reciprocal Co-IP, FBXL2-insensitive IP3R3 knock-in cells, Ca²⁺ imaging, xenograft model, Pten⁻/⁻ MEFs

    PMID:28614300

    Open questions at the time
    • Whether IP3R1/IP3R2 isoforms are also FBXL2 substrates was not tested
    • The precise degron on IP3R3 was not fully mapped
  7. 2020 High

    Characterization of FUNDC1 as an FBXL2-stabilizing partner and of SP1-dependent transcriptional activation of Fbxl2 (suppressed by TNF-α/JNK) revealed that FBXL2 abundance is controlled at both protein-stability and transcriptional levels, with direct consequences for cardiac function and myogenesis.

    Evidence Co-IP with domain truncations, MS, FUNDC1⁻/⁻ mouse cardiac model, ChIP, EMSA, promoter-reporter assays, JNK inhibition

    PMID:32205409 PMID:32938669

    Open questions at the time
    • How FUNDC1 mechanistically protects FBXL2 from degradation is not defined
    • Whether SP1-mediated transcription is the sole transcriptional input is unknown
  8. 2021 High

    The demonstration that FBXL2 targets EGFR (including TKI-resistant mutants) for degradation — antagonized by the chaperone Grp94 — and that nebivolol upregulates FBXL2 function, provided a therapeutic strategy to overcome RTK-driven drug resistance in NSCLC.

    Evidence Co-IP, ubiquitination assay, overexpression/knockdown, GGTi-2418 and nebivolol treatment, xenograft model

    PMID:34635651

    Open questions at the time
    • The mechanism by which nebivolol upregulates FBXL2 is not delineated
    • Whether Grp94 blocks FBXL2 access to other RTK substrates is untested
  9. 2022 Medium

    Extension of the substrate repertoire to transcription factors T-bet and E47 established FBXL2 as a regulator of adaptive immunity (T-bet in allograft rejection) and cancer stemness (E47 in breast cancer), broadening its functional scope beyond cell cycle and inflammatory signaling.

    Evidence Co-IP, ubiquitination assays, dose-response, orthotopic lung transplant model, mammosphere formation, xenograft with nebivolol

    PMID:36113884 PMID:36460773

    Open questions at the time
    • The degrons in T-bet and E47 recognized by FBXL2 are not mapped
    • Independent replication by other laboratories is lacking
  10. 2023 Medium

    Showing that FBXL2 ubiquitinates both NLRP3 and pro-IL-1β (but not pro-caspase-1) to suppress inflammasome-driven IL-1β secretion identified FBXL2 as a dual checkpoint in inflammasome priming, reinforced by FBXO3 inhibitor stabilization of FBXL2.

    Evidence Co-IP, ubiquitination assay, MG-132 rescue, BC-1215 treatment in LPS-primed macrophages

    PMID:37004285

    Open questions at the time
    • The degrons on NLRP3 and pro-IL-1β are not identified
    • In vivo inflammatory disease model validation is absent
    • Single-laboratory finding awaiting independent confirmation
  11. 2026 High

    Identification of HER2 K747 as the FBXL2-targeted ubiquitination site and demonstration that blocking FBXL2 membrane localization (via geranylgeranyl transferase inhibitors) upregulates HER2 surface expression in HER2-low TNBC provided a pharmacologically actionable mechanism linking FBXL2 to HER2-targeted therapy eligibility.

    Evidence K747 site-directed mutagenesis, ubiquitination assay, Co-IP, GGTi-2418/ketoconazole treatment, xenograft with LNP delivery

    PMID:41612000

    Open questions at the time
    • Whether FBXL2-mediated HER2 degradation operates in all breast cancer subtypes is unknown
    • Structural basis for K747 selectivity is not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • No high-resolution structure of FBXL2 or an FBXL2-substrate complex exists, leaving the structural basis of its unusually broad substrate recognition — including how the leucine-rich repeat domain engages calmodulin-binding motifs and non-phosphodegron sequences — as a major unresolved question.
  • No crystal or cryo-EM structure of FBXL2
  • No systematic degron definition across the >15 reported substrates
  • Whether all substrates are direct or some are adaptor-mediated is untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 12
Localization
GO:0005886 plasma membrane 4 GO:0005794 Golgi apparatus 1 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-392499 Metabolism of proteins 12 R-HSA-1640170 Cell Cycle 4 R-HSA-168256 Immune System 3 R-HSA-162582 Signal Transduction 2 R-HSA-5357801 Programmed Cell Death 1
Partners
AURKBEGFRERBB2FBXO3FUNDC1ITPR3PIK3R2SKP1
Complex memberships
SCF(FBXL2)

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 FBL2 (FBXL2) is geranylgeranylated via its CAAX motif (CVIL) and forms a stable complex with HCV nonstructural protein NS5A; this interaction requires the CAAX motif but not the F-box domain, and geranylgeranylated FBXL2 is required for HCV RNA replication. [(3)H]mevalonate labeling, coimmunoprecipitation, dominant-negative overexpression, siRNA knockdown, wobble-mutant rescue Molecular cell High 15893726
2011 SCF(FBXL2) ubiquitinates and destabilizes cyclin D3 by recognizing a calmodulin (CaM)-binding motif within cyclin D3 (not a phosphodegron), leading to G2/M-phase arrest, supernumerary centrosomes, and apoptosis in lung cancer cells; calmodulin competes with FBXL2 for the same motif to protect cyclin D3. Overexpression, siRNA knockdown, polyubiquitination assays, cell cycle analysis, calmodulin competition assays, xenograft tumor model Oncogene High 22020328
2011 SCF(FBXL2) monoubiquitinates and degrades CCTα (CTP:phosphocholine cytidylyltransferase α) at the Golgi complex during Pseudomonas aeruginosa infection, reducing phosphatidylcholine synthesis; FBXL2 binds the CCTα IQ motif via its C-terminus, and calmodulin antagonizes this interaction by binding FBXL2 residues 80–90. Co-immunoprecipitation, siRNA knockdown, overexpression, calcium-dependent activation assays, murine P. aeruginosa infection model, calmodulin gene transfer Molecular and cellular biology High 21343341
2011 SCF(FBXL2) colocalizes with cyclin D3 at the centrosome and mediates cyclin D3 polyubiquitination and degradation, impairing cyclin D3 association with centrosomal assembly proteins Aurora A, Plk4, and CDK11, resulting in mitotic arrest. Co-localization imaging, RNAi knockdown, overexpression, cell cycle analysis Cell cycle Medium 22024926
2012 FBXL2 ubiquitinates and degrades cyclin D2 by targeting a calmodulin-binding signature within cyclin D2 (not a phosphodegron), causing G0 arrest and apoptosis in leukemic cells; calmodulin competes with FBXL2 for this motif to protect cyclin D2. siRNA knockdown, overexpression, polyubiquitination assay, calmodulin competition assay, cell cycle analysis Blood High 22323446
2012 FBXL2 binds the C-terminal fragment (CTF) of amyloid precursor protein (APP), promotes APP ubiquitination and proteasome-dependent degradation, inhibits APP endocytosis and localization in lipid rafts, and reduces Aβ peptide secretion; effects require an intact F-box domain. Overexpression, siRNA knockdown, co-immunoprecipitation, ubiquitination assay, APP localization studies, transgenic mouse model The Journal of neuroscience High 22399757
2013 FBXL2 interacts with the pool of p85β regulatory subunit of PI(3)K that is free of p110 catalytic subunits and targets it for ubiquitylation and proteasomal degradation; this requires the FBXL2 CaaX motif. Phosphorylation of p85β at Tyr655 inhibits its binding to FBXL2, while the phosphatase PTPL1 dephosphorylates p-Tyr655 to stimulate p85β degradation. FBXL2-mediated p85β degradation prevents competition with p85-p110 heterodimers for IRS1 and sustains PI(3)K signaling. F-box protein purification/MS, co-immunoprecipitation, ubiquitination assay, phosphorylation site mutagenesis, IRS1 binding assays, autophagy readout Nature cell biology High 23604317
2013 SCF(FBXL2) ubiquitinates Aurora B kinase at lysines K102, K103, and K207 within the midbody, promoting its degradation, mitotic arrest, and apoptosis; a triple-lysine mutant (K102/103/207R) resists SCF(FBXL2)-directed polyubiquitination. Co-immunoprecipitation, ubiquitination assay, lysine mutagenesis, overexpression, xenograft tumor model Cell death & disease High 23928698
2015 Fbxo3-dependent ubiquitination of Fbxl2 leads to Fbxl2 degradation, reducing Fbxl2-mediated ubiquitination of TRAF2; elevated TRAF2 then activates TNIK/GluR1 phosphorylation and GluR1 trafficking to the plasma membrane, contributing to neuropathic allodynia after spinal nerve ligation. siRNA knockdown, intrathecal drug administration (BC-1215 Fbxo3 inhibitor), behavioral allodynia testing, immunoprecipitation, western blotting The Journal of neuroscience Medium 26674878
2016 Fbxo3 inhibits Fbxl2-mediated ubiquitination of active zone protein RIM1α; deubiquitinated RIM1α accumulates in synaptic plasma membranes where it binds CaV2.2 and upregulates its expression, promoting neuropathic allodynia. siRNA knockdown, intrathecal BC-1215 administration, co-immunoprecipitation, electrophysiology (sEPSC), western blotting, behavioral testing The Journal of neuroscience Medium 27629721
2016 FBXL2 interacts with FoxM1 transcription factor (identified by tandem mass spectrometry) and promotes its ubiquitination and proteasomal degradation in gastric cancer cells, suppressing expression of FoxM1 targets Cdc25B and p27 and inhibiting cancer cell proliferation and invasion. Tandem mass spectrometry, co-immunoprecipitation, ubiquitination assay, overexpression/knockdown, proliferation/invasion assays FEBS letters Medium 26790640
2017 FBXL2 binds IP3R3 and targets it for ubiquitin-, p97-, and proteasome-mediated degradation, limiting Ca2+ transfer from the ER to mitochondria and preventing Ca2+-dependent apoptosis; PTEN competes with FBXL2 for IP3R3 binding to stabilize IP3R3, and FBXL2-insensitive IP3R3 knock-in mutant cells show increased cytosolic Ca2+ release and sensitization to apoptosis. Co-immunoprecipitation, ubiquitination assay, FBXL2-insensitive IP3R3 knock-in, FUNDC1/PTEN competition assays, Ca2+ imaging, xenograft model, Pten-/- MEFs Nature High 28614300
2017 FBXL2 mediates ubiquitination and degradation of TRAF6, and LIPUS strengthens this pathway to suppress inflammatory cytokine production in response to polyethylene debris. Gene overexpression, siRNA, western blotting, immunoprecipitation Scientific reports Low 28378753
2019 O-GlcNAcylation promotes ubiquitination and degradation of FBXL2 itself, which stabilizes its substrate FOXM1; FBXL2 ubiquitinates FOXM1 and the FBXL2-FOXM1 interaction is reduced by augmented O-GlcNAcylation (via OGA inhibitor Thiamet G). Co-immunoprecipitation, ubiquitination assay, OGA inhibitor treatment, overexpression/knockdown Biochemical and biophysical research communications Medium 31679690
2020 FUNDC1 interacts with FBXL2 (interaction requires the F-box domain of FBXL2); FUNDC1 loss accelerates FBXL2 degradation and increases IP3R3 levels, resulting in mitochondrial Ca2+ overload and cardiac dysfunction in obese hearts. Co-immunoprecipitation, mass spectrometry, truncation mutants (ΔF-box), FUNDC1-/- mouse, Ca2+ measurements Science advances High 32938669
2020 TNF-α suppresses Fbxl2 mRNA by activating JNK-mediated phosphorylation of SP1, which impairs SP1 binding to the Fbxl2 core promoter (bp -160 to +42); SP1 binding to the Fbxl2 promoter is required for skeletal myoblast differentiation. Chromatin immunoprecipitation, gel shift (EMSA), promoter-reporter assays, siRNA knockdown, JNK inhibition Molecular and cellular biology High 32205409
2021 FBXL2 targets EGFR (and TKI-resistant EGFR mutants) for proteasomal degradation; Grp94 protects EGFR by blocking FBXL2 binding. Disrupting FBXL2 membrane localization (via GGTi-2418) or upregulating FBXL2 (via nebivolol) destabilizes EGFR and suppresses NSCLC growth. Co-immunoprecipitation, ubiquitination assay, overexpression/knockdown, xenograft model, small-molecule functional studies Nature communications High 34635651
2022 FBXL2 polyubiquitinates T-bet transcription factor and co-immunoprecipitates with T-bet; FBXL2 overexpression reduces T-bet protein levels in a dose-dependent manner. TNF-α negatively regulates FBXL2 at both protein and mRNA levels during lung allograft rejection. Co-immunoprecipitation, ubiquitination assay, transfection dose-response, orthotopic mouse lung transplant model, costimulation blockade Journal of immunology Medium 36113884
2022 FBXL2 targets the transcription factor E47 for polyubiquitin- and proteasome-mediated degradation, inhibiting breast cancer stem cell (BCSC) stemness and paclitaxel resistance; nebivolol activates FBXL2 to overcome BCSC-driven resistance in vivo. Overexpression/knockdown, ubiquitination assay, mammosphere formation, xenograft model, nebivolol treatment Oncogene Medium 36460773
2023 FBXL2 binds, ubiquitinates, and promotes proteasomal degradation of both NLRP3 and pro-IL-1β (but not pro-caspase-1), suppressing ATP-induced IL-1β secretion in LPS-primed macrophages; this is upregulated by BC-1215 (FBXO3 inhibitor). Co-immunoprecipitation, ubiquitination assay, proteasome inhibitor (MG-132) rescue, western blotting Biochemical and biophysical research communications Medium 37004285
2026 FBXL2 promotes polyubiquitination of HER2 at lysine K747 and its proteasomal degradation; blocking FBXL2 membrane localization (via GGTi-2418 or ketoconazole, which inhibit geranylgeranyl transferase) elevates HER2 plasma membrane expression in HER2-IHC 0 TNBC cells. Ubiquitination assay, site-directed mutagenesis (K747), co-immunoprecipitation, small-molecule inhibitor studies, xenograft model with LNP delivery Nature cancer High 41612000

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Molecular cell 243 15893726
2017 PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth. Nature 206 28614300
2020 FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity. Science advances 114 32938669
1996 Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. Journal of virology 112 8892898
2013 FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nature cell biology 109 23604317
2012 F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 85 22323446
2011 F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene 66 22020328
2013 Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis. Cell death & disease 56 23928698
2012 FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis. The Journal of neuroscience : the official journal of the Society for Neuroscience 56 22399757
1993 Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. Journal of virology 56 7687300
2021 FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Nature communications 52 34635651
2011 Calmodulin antagonizes a calcium-activated SCF ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant homeostasis. Molecular and cellular biology 47 21343341
2015 Fbxo3-Dependent Fbxl2 Ubiquitination Mediates Neuropathic Allodynia through the TRAF2/TNIK/GluR1 Cascade. The Journal of neuroscience : the official journal of the Society for Neuroscience 35 26674878
2011 FBXL2 is a ubiquitin E3 ligase subunit that triggers mitotic arrest. Cell cycle (Georgetown, Tex.) 33 22024926
2016 Spinal Fbxo3-Dependent Fbxl2 Ubiquitination of Active Zone Protein RIM1α Mediates Neuropathic Allodynia through CaV2.2 Activation. The Journal of neuroscience : the official journal of the Society for Neuroscience 30 27629721
2021 FOSL1 promotes tumorigenesis in colorectal carcinoma by mediating the FBXL2/Wnt/β-catenin axis via Smurf1. Pharmacological research 29 33450386
2016 F-box protein FBXL2 inhibits gastric cancer proliferation by ubiquitin-mediated degradation of forkhead box M1. FEBS letters 28 26790640
1993 Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. Journal of immunology (Baltimore, Md. : 1950) 27 8496592
1994 Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. Journal of virology 26 7525983
2020 MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway. Life sciences 21 31953162
2017 Low-intensity pulsed ultrasound (LIPUS) prevents periprosthetic inflammatory loosening through FBXL2-TRAF6 ubiquitination pathway. Scientific reports 20 28378753
2019 Circular RNA SMARCA5 inhibits gastric cancer progression through targeting the miR-346/ FBXL2 axis. RSC advances 16 35515212
2020 Tumor Necrosis Factor Alpha Regulates Skeletal Myogenesis by Inhibiting SP1 Interaction with cis-Acting Regulatory Elements within the Fbxl2 Gene Promoter. Molecular and cellular biology 15 32205409
2022 FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance. Oncogene 14 36460773
2019 Poly-(γ-glutamic acid) Production and Optimization from Agro-Industrial Bioresources as Renewable Substrates by Bacillus sp. FBL-2 through Response Surface Methodology. Biomolecules 13 31756993
1995 A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. Journal of virology 13 7474084
1989 Characterization of a CD4(L3T4)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumor cell. Immunobiology 13 2483152
2014 A lack of association between polymorphisms of three positional candidate genes (CLASP2 , UBP1, and FBXL2) and canine disorder of sexual development (78,XX; SRY -negative). Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 7 24994500
2023 BC-1215 inhibits ATP-induced IL-1β secretion via the FBXL2-mediated ubiquitination and degradation of not only NLRP3, but also pro-IL-1β in LPS-primed THP-1 cells. Biochemical and biophysical research communications 6 37004285
2019 O-GlcNAcylation-mediated degradation of FBXL2 stabilizes FOXM1 to induce cancer progression. Biochemical and biophysical research communications 6 31679690
1998 Induction of cross-reactivity in an endogenous viral peptide non-reactive to FBL-3 tumor-specific helper T-cell clones. Microbiology and immunology 4 9719100
2022 Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-α during Acute and Chronic Lung Allograft Rejection. Journal of immunology (Baltimore, Md. : 1950) 3 36113884
1994 Effects of non-MHC background genes on the induction of CD4+ T cells that prevent rejection of a highly immunogenic tumor, FBL-3. International immunology 3 7916205
2024 Methylation regulation for FUNDC1 stability in childhood leukemia was up-regulated and facilitates metastasis and reduces ferroptosis of leukemia through mitochondrial damage by FBXL2. Open medicine (Warsaw, Poland) 2 38947217
2024 FUNDC1 mediated mitochondria-dependent ferroptosis of epithelial cells in model of asthma by FBXL2/ar/GPX4 signaling pathway of SUMO1 at K136. International reviews of immunology 2 39323222
2026 Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan. Nature cancer 1 41612000
2025 Scutellarin mitigates high glucose-induced pyroptosis in diabetic atherosclerosis: Role of Nrf2-FBXL2-mediated NLRP3 degradation. Endocrine journal 1 40010729
2010 [Establishment of an erythroleukemia model in CB6F1 mice by transplant with haploidentical mouse leukemic cell line FBL-3]. Zhongguo shi yan xue ye xue za zhi 0 21129245
1980 Regulation of the in vitro secondary cell-mediated cytotoxic response against syngeneic FBL-3 leukemia by macrophages. Microbiology and immunology 0 6968022